Evaluating of IL-34 as a Biomarker for Asthma in Children: Findings from Dhi Qar Province, Iraq
DOI:
https://doi.org/10.46966/msjar.v5i3.227Keywords:
Asthma, Interleukin-34, Respiratory Disorder, Risk Factors, Immune BiomarkerAbstract
Objective: To investigate the possible role of interleukin-34 in development of asthma in children and determine its effectiveness as a biomarker for monitoring disease severity. Methods: the current study focused on asthmatic children who were admitted to the two hospitals in Dhi-Qar province: Muhammad Al-Moussawi Children's Hospital, Bint Al-Huda Teaching Hospital for Women and Children. The period of study was placed between December 2023 to March 2024. Specifically included (85) asthmatic children’s patients, their ages ranged from 6 months to 6 years old. To compare the results with healthy control subjects (85) children of the same ages and sex as the patients were randomly selected from the local community and hospital. The concentration level of serum interleukin-34 was measured by Enzyme-linked immunosorbent assay (ELISA). Results: the present study revealed a striking difference in IL-34 concentrations between asthma patients and controls. Asthma patients exhibited significantly elevated IL-34 levels (409.4±114.7 pg/ml) compared to their healthy counterparts (307.6±56.43 pg/ml), with a p-value of <0.001.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Atyaf Ali Kadhim , Thikra Abdullah Mahmood
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
